Cathay International Holdings Ld Clarification Announcement - transaction in Shares (3910X)

TIDMCTI

RNS Number : 3910X

Cathay International Holdings Ld

05 May 2016

Cathay International Holdings Limited

("Cathay", the "Company")

Clarification Announcement - transaction in Shares held by a Director

Hong Kong, 5 May 2016 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and leading operator and investor in the growing healthcare sector in the People's Republic of China, announces that on 19 November 2015 Mr Wu Zhen Tao, the Chairman of the Company, acquired 580,890 common shares in the Company. Mr Wu subsequently acquired 306,000 common shares in the Company on 27 November 2015 (together, being the "November Shares"). Full details of the purchases are included in the DTR3 annexes being released concurrently with this announcement.

The Company notes that due to an administrative error, the Company failed to make announcements of the respective purchases of the November Shares within the timeframe required pursuant to DTR 3.1.4R. The Company confirms that Mr Wu's interest in common shares set out in its Annual Report and Accounts for the financial year ended 31 December 2015, released on 22 April 2016, included the November Shares and was therefore correct.

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

Tel: [phone]

N+1 Singer

Aubrey Powell / Lauren Kettle - Corporate Finance

Brough Ransom - Sales

Tel: [phone]

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

Tel: [phone]

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China ("PRC").

The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in China and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, China's leading specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a company engaged in the manufacture, marketing and sales of inositol and its by-product, dicalcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment.

For more information please visit the Company's website: www.cathay-intl.com.hk

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCKMGGKMKKGVZM

(END) Dow Jones Newswires

May 05, 2016 08:00 ET (12:00 GMT)